• Science
  • Pipeline
  • About Us
  • News & Media
  • Resources
  • Investors
  • Contact Us
  • Science
  • Pipeline
  • About Us
  • News & Media
  • Resources
  • Investors
  • Contact Us
Mobile close button Mobile toggle button

Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer, Nature Oncogene, 20 May 2020

steve | 30 May 2020
Categories:

Post navigation

← Final Results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2- metastatic breast cancer (mBC), Annals of Oncology, 1 October 2019
Can Activation of NRF2 Be a Strategy against COVID-19? Trends in Pharmacological Sciences, September 2020 →
Copyright© 2023
  • Privacy Policy
  • Sitemap
Twitter Twitter linkedin linkedin
Get in touch